The 30th Conference on Retroviruses and Opportunistic Infections (CROI) was held February 19-22, 2023, in Seattle, Washington. Learn more about CROI 2023 and the exciting work of our CHIPTS scientists featured at the conference below.

What is CROI 2023?

CROI 2023 provides a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. CROI is the preeminent HIV research meeting in the world and includes up to 4,000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

CHIPTS at CROI 2023

CHIPTS Co-Director and Combination Prevention Co-Director Dr. Raphael J. Landovitz was part of the team of experts selected to be part of this year’s CROI Scientific Program Committee (PC). The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

During the conference, Dr. Landovitz presented during the pre-conference workshop on “Advances in Biomedical Prevention of HIV.”

Dr. Landovitz’s work was also featured in several other presentations and posters as the Protocol Chair of the HPTN 083 study:

  • Oral Abstract Session (#8): All Modes Lead to PrEP – Tuesday, February 21, 2023 from 10:00AM-12:00PM
    • The Levi Syndrome Characteristics of Early HIV Infection with Cabotegravir for PrEP
    • Cabotegravir for HIV PrEP in US Black and Transgender women who have sex with men
  • Poster Session-V4: PrEP use in Special Populations – Tuesday, February 21, 2023 from 2:30 PM-4:00 PM
    • Bone Density Changes with CAB-LA or TDF/FTC PrEP in MSM and TGW in HPTN 083
    • Poster Session (#6) PrEP Product Update and Effectiveness
    • PrEP Product Choice in US Participants in HPTN083

CHIPTS Combination Prevention Core Scientist Dr. Kara W. Chew also shared an engaging presentation at this year’s conference on “Future Directions in Outpatient Therapy for Mild to Moderate COVID-19″ during Symposium #5 – COVID-19: Where are we now? Additionally, Dr. Chew presented a poster focused on the “Reduction in HIV Reservoir Markers with GAG/POL/IL-12 DNA Therapeutic Vaccination.”

Dr. Chew’s work on multiple studies was featured as part of several other oral and poster presentations:

  • Symposium (#5) COVID-19: Where are we now?
    • Characterization of Single Versus Dual Active MAB Against SARS-Cov-2
    • Saftey and Efficacy of Inhaled Interferon-B1A (SNG001) in Outpatients with COVID-19
    • Symptoms and Viral Rebound in Untreated COVID-19 Infection
  • Poster Session-N1 PASC (LONG COVID)
    • Post-Acute COVID Outcomes: Amubarvimab/ Romlusevimab vs Placebo in the Activ-2 Trial
  • Poster Session-B7 LONG COVID
    • Plasma Antibody and N Antigen Status Predict Outcomes in Outpatients with COVID-19

To learn more about CROI 2023, check out their conference program: https://www.croiconference.org/wp-content/uploads